Moreover, CML-BC patients had a much lower miR-320 expression in intracellular levels but higher in plasma exosomal levels, compared to CML-CP patients (Figure 8C), which might be explained by the higher expression of HNRNPA1 in CML-BC cells. The gene discussed is HNRNPA1; the disease is breast cancer.